XML 30 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 31, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Jun. 18, 2013
Significant Accounting Policies [Line Items]
Common stock, par value per share		$ 0.001	$ 0.001	$ 0.001	$ 0.001
Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive		19,820,485	18,661,182	19,797,190	18,781,572
Brazil Agreement [Member] | Protalix Ltd. [Member] | Fiocruz [Member]
Significant Accounting Policies [Line Items]
Supply commitment for entitled rights to be received						$ 280.0
Percentage of adult Gaucher patients in Brazil currently treated with Uplyso				10.00%
Agent fee, percentage of net proceeds				5.00%
Pfizer Agreement [Member] | Pfizer Incorporation [Member]
Significant Accounting Policies [Line Items]
Agreement, future revenues and expenses sharing percentage		60.00%		60.00%
Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member]
Significant Accounting Policies [Line Items]
Agreement, future revenues and expenses sharing percentage		40.00%		40.00%
Subsequent Event [Member] | Amended Pfizer Agreement [Member]
Significant Accounting Policies [Line Items]
Proceeds from sale of share in the collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso	$ 36.0
Subsequent Event [Member] | Amended Pfizer Agreement [Member] | Pfizer Incorporation [Member] | Excluding Brazil [Member]
Significant Accounting Policies [Line Items]
Agreement, future revenues and expenses sharing percentage	100.00%
Subsequent Event [Member] | Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member]
Significant Accounting Policies [Line Items]
License and supply agreement potential future payment, elimination amount	$ 12.5
Subsequent Event [Member] | Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | BRAZIL
Significant Accounting Policies [Line Items]
Agreement, future revenues and expenses sharing percentage	100.00%

X

- Definition

The Company will pay a fee equal to percentage of the net proceeds generated in Brazil to its agent for services provided in assisting us complete the Brazil Agreement pursuant to an agency agreement between the agent and the Company.

+ References

No definition available.

+ Details

Name:	plx_AgentFeePercentageOfNetProceeds
Namespace Prefix:	plx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaborative arrangement revenues and expense sharing percentage.

+ References

No definition available.

+ Details

Name:	plx_CollaborativeArrangementRevenuesExpensesSharingPercentage
Namespace Prefix:	plx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

The Amended Pfizer Agreement eliminates Pfizer's entitlement to annual payments in relation to commercialization of Elelyso in Brazil.

+ References

No definition available.

+ Details

Name:	plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Represents the percentage of adult Gaucher patients treated with Uplyso.

+ References

No definition available.

+ Details

Name:	plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso
Namespace Prefix:	plx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment amount.

+ References

No definition available.

+ Details

Name:	plx_ProceedsFromSaleOfShareInCollaboration
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The floor purchase amount that one or more customers of the entity must satisfy in order to be entitled to certain rights under the terms of disclosed arrangements.

+ References

No definition available.

+ Details

Name:	plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- References

No definition available.

+ Details

Name:	plx_SignificantAccountingPoliciesLineItems
Namespace Prefix:	plx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef



-Publisher FASB



-Name Accounting Standards Codification



-Glossary Antidilution



-URI http://asc.fasb.org/extlink&oid=6505113



Reference 2: http://www.xbrl.org/2003/role/presentationRef



-Publisher FASB



-Name Accounting Standards Codification



-Glossary Diluted Earnings Per Share



-URI http://asc.fasb.org/extlink&oid=6510752



Reference 3: http://www.xbrl.org/2003/role/presentationRef



-Publisher FASB



-Name Accounting Standards Codification



-Glossary Contingent Stock Agreement



-URI http://asc.fasb.org/extlink&oid=6508534



Reference 4: http://www.xbrl.org/2003/role/presentationRef



-Publisher FASB



-Name Accounting Standards Codification



-Topic 260



-SubTopic 10



-Section 50



-Paragraph 1



-Subparagraph (c)



-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name:	us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef



-Publisher FASB



-Name Accounting Standards Codification



-Topic 210



-SubTopic 10



-Section S99



-Paragraph 1



-Subparagraph (SX 210.5-02.29)



-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682



Reference 2: http://www.xbrl.org/2003/role/presentationRef



-Publisher SEC



-Name Regulation S-X (SX)



-Number 210



-Section 02



-Paragraph 30



-Article 5

+ Details

Name:	us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_BrazilAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=us-gaap_SubsidiariesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=plx_FiocruzMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=plx_PfizerIncorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementGeographicalAxis=plx_ExcludingBrazilMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementGeographicalAxis=country_BR
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: